Claims
- 1. A quinoxaline compound having the formula I ##STR7## wherein R.sup.1 is C.sub.1-12 -alkyl, which may optionally be substituted by hydroxy, formyl, carboxy, carlomoyl, piperedino, amino, C.sub.3-8 -cycloalkyl, or phenyl; or R is C.sub.3-6 cycloalkyl and in any case
- R.sup.5 and R.sup.6 together form a further fused benzene ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.7 and R.sup.8 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 -alkyl; or
- R.sup.7 and R.sup.8 together form a further fused benzene ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.5 and R.sup.6 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 -alkyl.
- 2. A compound of claim 1, which is 4-methylbenzo[f]quinoxaline-2,3(1H,4H)-dione.
- 3. A compound of claim 1, which is 4-butylbenzo[f]quinoxaline-2,3(1H,4H)-dione.
- 4. A compound of claim 1, which is 4-(2-piperidinoethyl) benzo[f]quinoxaline-2,3(1H,4H)-dione.
- 5. A compound of claim 1, which is 4-cyclohexylbenzo[f]-quinoxaline-2,3(1H,4H)-dione.
- 6. A compound of claim 1, which is 1-methyl-6,7-dinitrobenzo[f]-quinoxaline-2,3(1H,4H-dione.
- 7. A pharmaceutical composition useful as a neuroleptic comprising as active component a neuroleptically effective amount of a quinoxaline compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition according to claim 7 in the form of an oral dosage unit containing about 50-200 mg of the active compound.
- 9. A method of treating hyperactivity of the excitatory neurotransmitters in a subject in need thereof, which comprises the step of administering to the said subject a neuroleptically-effective amount of a compound of claim 1 or a pharmaceutically-acceptable salt thereof.
- 10. A method according to claim 9 wherein the compound is administered in the form of an oral dosage unit containing about 50 to 200 mg of the compound.
- 11. A method of claim 9, wherein the compound is administered in the form of a pharmaceutical composition containing the same together with a pharmaceutically-acceptable carrier.
- 12. A method of claim 9, wherein the neurotransmitters treated are the quisqualate receptors and the amount of the compound administered is a quisqualate-antagonistic amount of the compound.
Priority Claims (2)
Number |
Date |
Country |
Kind |
5862/87 |
Nov 1987 |
DKX |
|
1422/88 |
Mar 1988 |
DKX |
|
Parent Case Info
This is a continuation of application Ser. No. 268,939, filed Nov. 8, 1988, now U.S. Pat. No. 4,948,749, issued Aug. 14, 1990.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
3431111 |
Brooker et al. |
Mar 1969 |
|
4889855 |
Jacobsen et al. |
Dec 1989 |
|
4912108 |
Jacobsen et al. |
Mar 1990 |
|
4948794 |
Honore et al. |
Aug 1990 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
283959 |
Sep 1988 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Jacobsen et al., Chemical Abstracts, vol. 110, No. 75568 (1989) (Abstract for EP283959). |
Yamatani et al., Chemical Abstracts, vol. 73, No. 131029 and 131031 (1970). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
268939 |
Nov 1988 |
|